Drug Profile
Cilostazol - Otsuka Pharmaceutical
Alternative Names: OPC-13013; OPC-21; Pletaal; PletalLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Developer Otsuka Pharmaceutical; Pfizer
- Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
- Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
- Discontinued Angina pectoris; Coronary artery disease; Coronary artery restenosis
Most Recent Events
- 13 Nov 2020 Otsuka Pharmaceutical completes phase I CiloMecT trial in Healthy volunteers (Adjunctive therapy) in Germany (PO) in March 2020 (EudraCT2013-002633-38) (NCT02554721)
- 21 Sep 2017 No development reported - Phase-III for Angina pectoris (In the elderly, Treatment-experienced, In adults) in South Korea (PO)
- 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)